Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease

Value in Health

Volumn 13, Issue 2, 2010, Pages 188-195

  Punekar, Yogesh Suresh ^a   Sunderland, Thomas ^b   Hawkins, Neil ^c   Lindsay, James ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ICON PLC   (United Kingdom)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Cost effectiveness; Crohn's disease; Infliximab; Pediatric

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONEY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 77149168736     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00658.x     Document Type: Article

References (38)

1. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999 28 : 445 458.
2. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999 28 : 255 281.
3. Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am 2003 32 : 967 995.
4. Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology 2004 126 : 1550 1560.
5. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004 53 : 1471 1478.
6. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997 32 : 1134 1139.
7. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000 342 : 1627 1632.
8. Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005 17 : 1047 1052.
9. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007 132 : 863 873.
10. Harvey R, Bradshaw J. A simple index for Crohn's disease activity. Lancet 1980 1 : 514.
11. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976 70 : 439 444.
12. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006 55 (Suppl. 1 i36 58.
13. Hyams J, Ferry G, Mandel F, et al. Development and validation of a paediatric Crohn's diseases activity index. J Pediatr Gastroenterol Nutr 1991 12 : 439 447.
14. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 1549.
15. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337 : 1029 1035.
16. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007 13 : 481 489.
17. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004 19 : 749 754.
18. Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006 55 : 1124 1130.
19. Office of National Statistics. Life tables for England and Wales 2002-2004. Available from: http://www.statistics.gov.uk/downloads/theme- population/LE-E&W-2006.xls Last [Accessed November 21, 2007].
20. NICE TAG 104. Etanercept and infliximab for the treatment of adults with psoriatic arthritis. Technology Appraisal Guidance 104; London, July 2006.
21. Reference costs 2006/07. National schedule of reference costs. Department of Health, January 2008.
22. Lichtenstein G, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalisations and surgery. Am J Gastroneterol 2004 99 : 91 6.
23. Casellas F, Arenas J, Baudet J. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005 11 : 488 496.
24. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 35 : 1095 1108.
25. National Institute of Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London : NICE, April 2004 26.
26. Sonnenberg F, Beck R. Markov models in medical decision making: a practical guide. Med Decis Making 1993 13 : 322 339.
27. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 350 : 876 885.
28. Arseneau KO, Cohn SM, Cominelli F, Connors AF. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001 120 : 1640 1656.
29. Clark W, Raftery J, Song F, et al. A systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess 2003 7 : 1 67.
30. Jaisson-Hot I, Flourié B, Descos L, Colin C. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004 20 : 274 279.
31. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007 26 : 1509 1520.
32. Lindsay J, Punekar Y, Morris J, et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modeling outcomes in active luminal and fistulising disease in adults. Aliment Pharmacol Ther 2008 28 : 76 87.
33. Hanauer SB, Cohen RD, Becker RV 3rd., et al. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther 1998 20 : 1009 1028.
34. FDA News. FDA approves Remicade for children with Crohn's disease. May 19, 2006. Available from: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01376.html [Accessed June 19, 2008].
35. Gregor JC, McDonald JWD, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997 3 : 265 276.
36. Woehl A, Hawthorne B, Morgan C, et al. The epidemiology and healthcare resource use in patients with Crohn's disease: a population based UK study. Value Health 2007 10 : A355.
37. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002 35 : 151 156.
38. Saro C, da la Coba C, Casado MA, et al. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther 2007 26 : 1313 1323.